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Abstract 
 
ESAC, the EURL ECVAM Scientific Advisory Committee, advises EURL ECVAM on scientific 
issues. Its main role is to conduct independent peer review of validation studies of 
alternative test methods and to assess their scientific validity for a given purpose. The 
committee reviews the appropriateness of study design and management, the quality of 
results obtained and the plausibility of the conclusions drawn. ESAC peer reviews are 
formally initiated with a EURL ECVAM Request for ESAC Advice, which provides the 
necessary background for the peer-review and establishes its objectives, timelines and 
the questions to be addressed. The peer review is normally prepared by specialised ESAC 
Working Groups. These are typically composed of ESAC members and other external 
experts relevant to the test method under review. These experts may be nominated by 
ESAC, EURL ECVAM and partner organisations within the International Cooperation on 
Alternative Test Methods (ICATM). ESAC ultimately decides on the composition of these 
Working Groups. ESAC's advice to EURL ECVAM is formally provided as 'ESAC Opinions' 
and 'Working Group Reports' at the end of the peer review. ESAC may also issue 
Opinions on other scientific issues of relevance to the work and mission of EURL ECVAM 
but not directly related to a specific alternative test method.   
The ESAC Opinion expressed in this report relates to the peer-review of the BASF-
coordinated Performance Standards-based validation of the LuSens test method for skin 
sensitisation testing. 
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Ispra, 24 June 2016 
ESAC Opinion 
 
In April 2016, the EURL ECVAM Scientific Advisory Committee (ESAC) (Annex 1) received 
from EURL ECVAM a request for scientific advice on the BASF-coordinated Performance 
Standards-based validation of the LuSens test method for skin sensitisation testing 
(Annex 2). ESAC established a working group (WG) (Annex 1) which delivered an ESAC 
WG report dated 6 June 2016 (Annex 3). 
At its 42nd meeting, held on the 9th and 10th June 2016 at EURL ECVAM, Ispra, Italy, the 
non-Commission members of ESAC unanimously endorsed the following statement which 
was based on the ESAC WG report: 
The replacement of traditional animal-based test methods by alternative ones should 
ideally be one-to-one replacements. However, the replacement of traditional animal-
based test methods for skin sensitisation by animal-free approaches is likely to require 
an Integrated Approach to Testing and Assessment (IATA). This combines reliable and 
mechanistically relevant test methods addressing the currently recognised key events in 
the adverse outcome pathway for skin sensitisation induction (OECD, 2012; OECD, 
2016a, b).   
Currently, three animal-free test methods have been validated becoming OECD Test 
Guidelines (TG). The DPRA (TG 442C) provides information about the capacity of the 
chemical to react with cysteine and/or lysine groups (key event 1). The KeratinoSens™ 
test method (TG 442D) addresses skin inflammation by assessing the impact of a 
substance on ARE mediated Nrf2 activation (key event 2). The h-CLAT (TG 442E) 
addresses key event 3 by measuring the up-regulation of cell membrane markers CD86 
and CD54 to predict a skin sensitisation potential. 
The test method under evaluation (LuSens) addresses key event 2 by measuring ARE 
mediated activation of luciferase used as a surrogate for the Nrf2 gene. This test method 
is therefore very similar to the KeratinoSens™ method. 
The validation study of the LuSens method was performed according to the existing 
guidelines for a formal inter-laboratory study using Performance Standards (OECD, 2005; 
OECD, 2015). The LuSens test method was apparently easily transferred and showed 
very good within- and between-laboratory reproducibility (100 % concordance in both 
cases). In contrast, the LuSens scored both methyl salicylate and eugenol differently 
compared to KeratinoSens™ and, with a sensitivity of 92 %, a specificity of 75 % and an 
accuracy of 85 %, it did not comply with one of the Performance Standards 
requirements: sensitivity ≥ 80 %, specificity ≥ 80 % and accuracy ≥ 80 %. 
Careful analysis of the individual run data for methyl salicylate and eugenol, however, 
showed that both sensitiser and non-sensitiser predictions occurred with either 
KeratinoSens™ or LuSens (Annex 2, Table 1). 
On the basis of 18 out of 20 reference substances being classified correctly, and the two 
discordant substances being borderline substances (Kolle et al., 2013), ESAC cannot see 
any scientific reason for choice of one method over the other, suggesting informed test 
method selection may be based more on price and availability. The LuSens test 
developers agreed to specify on their web site that the cell line, as well as its quality 
assessment, are available free of charge. 
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ESAC concludes that the LuSens test method, like the KeratinoSens™ test method, is 
ready to be considered for regulatory use in the context of an IATA for skin sensitisation 
and remains a useful tool for screening and early decision making during product 
development, within the applicability domain defined in the validation study.  
Of note, the ESAC also makes general recommendations on Performance Standards in a 
separate Opinion (ESAC, 2016), which are relevant to the current OECD Performance 
Standards on in vitro skin sensitisation ARE-Nrf2 Luciferase test methods (OECD Series 
on Testing and Assessment No. 213; OECD, 2015). 
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1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
R1 ESAC Peer Review  
of a Prevalidation Study or Validation Study 
YES, external validation study (i.e. not coordinated by 
EURL ECVAM) 
If R1)applies please specify further: 
►Prevalidation Study NO 
►Prospective Validation Study NO 
►Retrospective Validation Study NO 
►Validation Study based on Performance 
Standards 
YES 
The validation study is based on the OECD 
Performance Standards No. 213: "Performance 
Standards for Assessment of Proposed Similar or 
Modified In Vitro Skin Sensitisation ARE-NRF2 
Luciferase Test Methods (PS) (OECD 2015a)". The 
validation study was performed by the test method 
developer. 
R2 Scientific Advice on a test method submitted to 
EURL ECVAM for validation  
(e.g. the test method's biological relevance etc.) 
NO 
R3 Other Scientific Advice  
(e.g. on test methods, their use; on technical issues such as cell 
culturing, stem cells, definition of performance standards etc.) 
NO 
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2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE 
ESAC IS REQUESTED 
BASF PS-based validation of the LuSens assay for skin sensitisation testing 
 
 
3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
1) Background to skin sensitization and current regulatory adopted tests 
 
Skin sensitisation is the toxicological endpoint associated with substances that have the intrinsic 
ability to cause allergic contact dermatitis (ACD) in humans.  
 
The identification of the skin sensitisation potential represents an important component of the safety 
assessment of new and existing chemicals including cosmetic ingredients. Traditional regulatory 
predictive tests for skin sensitisation rely on the use of animals. These include: the guinea-pig tests 
(Buehler Test and Guinea-pig Maximisation Test) (OECD TG 406), the murine Local Lymph Node Assay 
(LLNA, OECD TG 429) and its non-radio-isotopic variants (OECD TG 422a and 422b). 
 
In recent years progress has been made in the development and regulatory adoption of alternative 
methods for skin sensitization hazard identification. Two methods validated and/or peer-reviewed by 
EURL ECVAM, the direct peptide reactivity assay (DPRA) and the KeratinoSens™ have been adopted 
by the OECD as Test Guidelines 442C and 442D respectively. A third method, the human Cell Line 
Activation Test is in the final stages of the OECD adoption process at the time of writing of this 
request. 
 
Methods developed in the area are addressing key chemical/biological mechanisms leading to the 
acquisition of skin sensitization. Such mechanisms have been described in the form of an Adverse 
Outcome Pathway (AOP; OECD 2010a, 2010b). Within the skin sensitisation AOP the molecular 
initiating event (i.e. the first key event - KE) is the covalent binding of electrophilic substances to 
nucleophilic centres in skin proteins. The second key event takes place in the keratinocytes and 
includes inflammatory responses as well as changes in gene expression associated with specific cell 
signalling pathways such as the antioxidant/electrophile response element (ARE)-dependent 
pathways. The third key event is the activation of dendritic cells (DC), typically assessed by expression 
of specific cell surface markers, chemokines and cytokines. The fourth key event is T-cell proliferation, 
which is indirectly assessed in the murine Local Lymph Node Assay (LLNA). 
 
The LuSens is proposed to address KE2 of the AOP. As for the other skin sensitization test methods 
evaluated by EURL ECVAM and adopted by the OECD, also the LuSens does not have the potential to 
function as a full-replacement stand-alone method. Instead, it is proposed that a combination of in in 
silico, in chemico and in vitro tests, addressing the key biological events of skin sensitisation, will be 
needed to achieve this goal. A defined approach to testing and assessment combining LuSens data 
with other information has been developed (Urbisch et al., 2015; Ramirez et al, 2014 and Bauch et al., 
2012). 
2) The LuSens test method 
The LuSens Assay is an in vitro reporter gene assay that is used to support the assessment of the 
sensitizing potential of a substance. It utilizes human skin cells harboring the luciferase reporter gene, 
to detect the induction of the cytoprotective responses elicited by the genes controlled by 
antioxidant response element; these can be activated by electrophilic stress by reactivity with 
EURL ECVAM REQUEST FOR ESAC ADVICE  Page | 12  
cysteine residues in the respective protein. Keratinocytes are the first cells exposed to a substance by 
skin penetration. The keap1 protein contains cystein residues which have been shown to be highly 
susceptible to haptenization by electrophilic sensitizers (see also the DPRA and KeratinoSensTM 
assays). In the presence of a hapten, the transcription factor Nrf2, which lies associated with keap1 in 
the cytoplasm, dissociates from keap1 and translocates to the nucleus. Nrf2 binds to the ARE 
response elements and activates the transcription of various downstream protective genes, e.g. 
glutathione (GSH). The keap1 protein therefore constitutes an intracellular sensor protein for 
'electrophilic stress' by cystein reactive substances. The LuSens assay uses this pathway to identify 
sensitizers which cause electrophilic stress in keratinocytes by coupling the ARE-response element to 
a luciferase gene. The luciferase activity triggered after 48 h incubation with a test substance is an 
indicator for the activation of the Keap1/Nrf2/ARE signaling pathway (Ade et al. 2009, Natsch 2011, 
Natsch & Emter 2008, Vandebriel et al. 2010). The 'activation' of keratinocytes is the key step 2 of the 
AOP of skin sensitization. The LuSens is considered a similar method to the validated and regulatory 
adopted KeratinoSensTM (TG 442D, OECD 2015b; EURL ECVAM, 2014). 
 
3) History of submissions 
The optimised test method was pre-submitted to EURL ECVAM in 2011. Following the assessment of 
this submission, EURL ECVAM requested additional information on the test method in order to be 
able to evaluate whether it qualified to proceed to step 2 of the submission process. This information 
was provided by the test submitter in January 2012 and reviewed by EURL ECVAM. Following this 
assessment, the test submitter was invited to proceed to step 2 of the EURL ECVAM submission 
process. The full submission was received by EURL ECVAM in March 2015. Subsequent to the 
evaluation of the LuSens TST, EURL ECVAM requested additional information/clarifications to be 
provided. The final TST was received by EURL ECVAM in December 2015.  
 
The 2015 full submission concerns a PS-based validation study conducted to fulfil the requirements 
laid down in the OECD Performance Standards (PS) for demonstrating comparable performance to 
those of the validated KeratinoSens™ (Ramirez et al., 2016) and adherence to the essential test 
methods components to demonstrate similarity with the validated method (KeratinoSens™). In 
addition to the data generated during the PS-based validation study, the submission reports historical 
data for an additional set of chemicals. 
 
The reproducibility (100%) within- and between-laboratories of the LuSens test method exceeded the 
criteria for reproducibility defined in the OECD PS. The LuSens also exceeded the 80% PS target values 
for the overall accuracy and sensitivitiy (LuSens, 85% accuracy and 92% sensitivitiy; actual for 
KeratinoSens™ based on the 20 reference substances 87.0% accuracy, 86.7% sensitivity) but failed to 
meet the 80% target value for the specificity (LuSens 75%; actual for KeratinoSens™  87.5%). As 
requested by the PS the accuracy values have been derived using a weighted calculation. 
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For the same set of PS substances the LuSens and the KeratinoSensTM assays overall correctly 
predicted 17 of the total of 20 test substances and wrongly predicted 3 test substances. Whereas the 
LuSens assay led to two false positive predictions (4-methoxy-acetophenone and methyl salicylate) 
and one false negative (phenyl benzoate), the KeratinoSensTM assay led to one false positive (4-
methoxy-acetophenone) and two false negative predictions (eugenol and phenyl benzoate). The only 
false negative prediction of the LuSens assay is a weak sensitizer. 
 
Conclusions of the Test Submitter on the information submitted to EURL ECVAM 
 
According to the test developer (BASF) the information submitted to EURL ECVAM for entering the 
peer-review process indicates that the LuSens assay can be transferred to naïve laboratories having 
experience in cell culture without on-site training. It has demonstrated to provide comparable 
accuracy to the KeratinoSensTM assay, whereby, showing remarkable reproducibility of 100%. A 
systematic comparison, using the same set of test substances, among the LuSens and 
KeratinoSensTM assays has demonstrated good concordance. A concordance of 94% was reached for 
52 test substances for which human data were available and 93% for the 61 test substances for which 
LLNA data were available (Ramirez et al., 2014). A more recent study has shown that from a similar 
set of 69 test substances, 61 provided the same overall outcome, resulting in an interchangeability of 
88%. When comparing the accuracy of the LuSens assay and the KeratinoSensTM assay for thesame 
20 PS of the OECD TG 442D lead to same results. Most importantly, the implementation of the LuSens 
assay in a testing strategy has demonstrated to also lead to comparable predictions as if the 
KeratinoSensTM assay would have been integrated in the testing strategy (Ramirez et al., 2014). 
Therefore, the LuSens has fulfilled to the best the requirements specified in the OECD TG 442D for 
me-too assay.  
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4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1  OBJECTIVE 
Objective 
Why does EURL 
ECVAM require 
advice on the 
current issue? 
The opinion of ESAC should conclude on the quality of the submitted Performance 
Standards-based validation study on LuSens, which addressed the reliability 
(transferability, within and between laboratory reproducibility) and the predictive 
capacity of the method. The opinion should conclude on the equivalence of the 
performance of the LuSens to that of the validated reference method as outlined 
in the Performance Standards. Overall, the ESAC opinion, based on the review of 
the submitted study dossier, should conclude on the adequacy of the LuSens to 
support the regulatory assessment of skin sensitisation. 
 
 
4.2  QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed in 
view of achieving 
the objective of 
the advice? 
1) DESIGN & CONDUCT OF STUDY: The ESAC is requested to review whether the 
study was conducted appropriately in view of the objective of the study. The study 
objective was to assess the following parameters in comparison to respective 
criteria outlined in the Performance Standards: 
1. the similarity of the method to the validated reference method  
2. the reproducibility of the method within laboratories (WLR) 
3. its transferability to other laboratories 
4. its reproducibility between laboratories (BLR) 
5. whether the predictive capacity of the method considering the validation 
study results and historical data is acceptable 
6. whether the overall performance of the method supports its use for the 
regulatory assessment of skin sensitisation 
7. whether the OECD Performance Standards No. 213 (OECD 2015a) are 
adequate for the assessment of proposed similar or modified in vitro skin 
sensitisation ARE-NrF2 luciferase test methods 
 
 
4.3  TIMELINES 
Timelines 
concerning this 
request 
When does EURL 
ECVAM require 
the advice? 
Timeline Indication 
Finalised ESAC Opinion required by: June 2016 
Request to be presented to ESAC by 
written procedure (e.g. due to 
urgency) prior to the next ESAC 
YES 
Request to be presented to ESAC at 
ESAC plenary meeting 
NO 
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5.  EURL ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN 
ESAC 
5.1  EURL ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIRED 
Specific 
structures 
required within 
ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to EURL ECVAM? 
(YES/NO) 
S1 ESAC Rapporteur NO 
S2 ESAC Working Group 
ESAC members 
- Erwin Roggen (Chair) 
- Annette Kopp-Schneider 
EURL ECVAM nominations 
- David Basketter (DABMEB Consultancy) 
- Steven Enoch (Liverpool John Moores 
University) 
ICATM nominations 
- Joanna Matheson (CPSC; nominated by 
ICCVAM) 
- Yong Heo (Catholic University of Daegu; 
nominated by KoCVAM) 
- Reiko Adachi (NIHS; nominated by 
JaCVAM) 
 
 
S3 Invited Experts NO 
Ad S3: If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
 
If other than above (S1-S3):   
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5.2  DELIVERABLES AS PROPOSED BY EURL ECVAM 
Deliverables 
What deliverables 
(other than the 
ESAC opinion) are 
required for 
addressing the 
request? 
Title of deliverable other 
than ESAC opinion 
Required? (YES/NO) 
D1 ESAC Rapporteur Report 
and draft opinion  
NO 
D2 ESAC Peer Review Report 
and draft opinion 
YES 
If other than above (D1-D2):  
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6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 
 
Count Description of document Already 
available? 
(YES/NO) 
File name 
1 Test Guideline 442D: In Vitro 
Skin Sensitisation: ARE-Nrf2 
Luciferase Test Method 
YES OECD TG442D 2015.pdf 
2 Performance Standards for 
assessment of proposed similar 
or modified in vitro skin 
sensitisation ARE-NrF2 luciferase 
test methods. Series on Testing 
and Assessment No. 213 
YES OECD STA213 2015.pdf 
3 Test Submission on the LuSens YES TST LuSens _Final_291215 (obsolete).pdf 
TST LuSens _Final_270416.pdf 
4 BASF reply to the EURL ECVAM 
comments 
YES Reply to ECVAM concerns on the Test 
Submission LuSen_291215.pdf 
5 Final EURL ECVAM assessment 
report 
YES TM2011_10_LuSens updated assessment 
report.pdf 
6 
LuSens protocol 
YES Attachment 1a_LuSens_Protocol_version 
24122015.pdf 
7 LuSens INVITTOX protocol YES Attachment 1b_INVITTOX_Final_291215.pdf 
8 Test items used to develop and 
optimise the test method 
YES Attachment 2_Test Chemicals_LuSens.pdf 
9 
Test items used to assess WLR 
YES Attachment 3_Test 
Chemicals_WLR_LuSens_inter-lab 
validation.pdf 
10 
Data used to assess WLR 
YES Attachment 4_WLR_Ramirez_2014.pdf 
See also attachments 18 (statistical report) 
11 
Test items used to assess 
transferability  
YES Attachment 5_REVISED_List of test 
items_Transferability_Final.pdf 
12 
Training protocol 
YES Attachment 
6_LuSens_Protocol_Final_13.06.13.pdf 
13 
Transfer protocol 
YES Attachment 7_LuSens 
Protocol_26.07.13.pdf 
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14 
Transfer report 
YES Attachment 8a_LuSens_Transferability 
Report.pdf 
Attachment 8b_LuSens_Transferability 
Report_non-blinded.pdf 
15 
Test items used for BLR assessment 
YES Attachment 9_REVISED_Test 
Chemicals_BLR_LuSens_inter-laboratory 
validation_Final.pdf 
16 
Data used for BLR and Predictive 
Capacity assessment  
YES See attachments 18 (statistical report) 
17 
Project plans 
YES Attachment 13a_LuSens Study Plan 
180613_Final.pdf 
Attachment 13b_REVISED_LuSens 
Experimental Design 150325 final.pdf 
18 
Scientific papers mentioned in the 
TST 
YES Attachment_17.pdf 
19 
Statistical reports 
YES Attachment 18a_Statistical Report LuSens 
catch-up validation labs coded final 
150320.pd 
Attachment 18b_Statistical Report LuSens 
catch-up validation final 150320.pdf 
Attachment 18c_Important Note_Phase II 
testing_230414. 
Annex A6 to Attachment 18_241215.pdf 
Attachment 18d_Data 
analysis_Template_LuSens_unprotected.xlsx 
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7. TERMS OF REFERENCE OF THE ESAC WORKING GROUP 
7.1 ESTABLISHMENT OF THE ESAC WORKING GROUP 
The ESAC unanimously agreed by written procedure on the 2nd of March 2016 on the composition of 
a new ESAC Working Group for the review of test methods in the area of skin sensitisation. 
 
7.2 TITLE OF THE ESAC WORKING GROUP 
Full title:  
ESAC Working Group on Skin Sensitisation Test Methods 
Abbreviated title:  
 
ESAC WG Sensitisation 
 
7.3 MANDATE OF THE ESAC WORKING GROUP 
The EWG is requested to conduct a scientific review of the LuSens PS-based validation study. The 
review needs to address the questions put forward to ESAC by EURL ECVAM. 
 
The review should focus on the quality of the submitted PS-based validation study on LuSens, which 
addressed the reliability (transferability, within and between laboratory reproducibility) and the 
predictive capacity of the method. The opinion should conclude on the equivalence of the 
performance of the LuSens to that of the validated reference method as outlined in the PS. 
 
7.4 DELIVERABLES OF THE ESAC WORKING GROUP 
The ESAC WG is requested to deliver to the chair of the ESAC and the ESAC Coordinator a detailed 
ESAC Working Group Report outlining its analyses and conclusions and a draft ESAC Opinion. A 
reporting template has been appended (Appendix 1) intended to facilitate the drafting of the report. 
 
The conclusions drawn in the report should be based preferably on consensus. If no consensus can 
be achieved, the report should clearly outline the differences in the appraisals and provide 
appropriate scientific justifications. 
 
7.5 PROPOSED TIMELINES OF THE ESAC WORKING GROUP 
Item Proposed date/time Action Deliverable 
1 17-19 May 2016 Working Group meeting  Draft ESAC WG report 
and draft ESAC opinion 
2 27 May 2016 Circulation of final WG report and 
draft ESAC opinion to ESAC 
Final draft ESAC WG 
report and draft ESAC 
opinion 
3 9-10 June 2016 Endorsement of WG report and 
ESAC opinion at ESAC42 meeting 
Final ESAC WG report 
and ESAC opinion 
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7.6 QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC WORKING GROUP 
The ESAC WG is requested to address the questions posed to the ESAC which have been broken 
down further in more specific questions by the ESAC chair, the chair of the ESAC WG and the 
Secretariat (see section 4.2). 
 
When preparing the final ESAC WG report to address these questions, the ESAC WG is requested to 
use a pre-defined reporting template. This template (see appendix 1) follows EURL ECVAM's modular 
approach and addresses to which extent the standard information requirements have been 
addressed by the study. The template allows moreover for addressing the issues specific studies 
outlined in section 4.2. The Secretariat will provide guidance if necessary. 
 
 
APPENDIX 1 REPORTING TEMPLATE 
The appended ESAC WG template suggests a structure that is in close agreement with the EURL 
ECVAM information requirements ("modules") for scientific review following validation and allows at 
the same time for the description of the analysis and conclusions concerning more specific questions.  
 
The template can be used for various types of validation studies (e.g. prospective full studies, 
retrospective studies, performance-based studies and prevalidation studies). Depending on the study 
type and the objective of the study, not all sections may be applicable.  
 
However, for reasons of consistency and to clearly identify which information requirements have not 
been sufficiently addressed by a specific study, this template is uniformly used for the evaluation of 
validation studies. 
 
The current template is 
 
TEMPLATE_ESAC-WG_REPORT-v6.doc 
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ESAC Working Group 
 
This report was prepared by the "ESAC Working Group for Skin Sensitisation" (ESAC WG SS), charged 
with conducting a detailed scientific peer review of on the BASF-coordinated Performance Standards-
based validation of the LuSens test method for skin sensitisation testing.  
 
The ESAC WG had the following members: 
 
ESAC members 
 Erwin Roggen (Chair) 
 Annette Kopp-Schneider 
 
EURL ECVAM nominations 
 David Basketter (DABMEB Consultancy) 
 Steven Enoch (Liverpool John Moores University) 
 
ICATM nominations 
 Yong Heo (Catholic University of Daegu; ICATM nomination by KoCVAM) 
 Reiko Adachi (NIHS; ICATM nomination by JaCVAM) 
 
ESAC Coordination: 
 João Barroso (ESAC Coordinator) 
 Silvia Casati 
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Abbreviations used in the document 
 BLR   Between-laboratory reproducibility 
 CI   Confidence Interval 
 EURL ECVAM  European Union Reference Laboratory for Alternatives to Animal  
Testing 
 ESAC   EURL ECVAM Scientific Advisory Committee 
 ESAC WG  ESAC Working Group 
 GLP   Good Laboratory Practice 
 IATA   Integrated Approach to Testing and Assessment 
 PS   Performance Standards 
 SOP   Standard Operating Procedure (used here as equivalent to 'protocol') 
 VMT   Validation Management Team 
 WLR   Within-laboratory reproducibility 
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1. Study objective and design 
1.1 Analysis of the clarity of the study objective's definition 
(a) ESAC WG summary of the study objective as outlined in the Test Submission 
From the project plan: 
Pre-validation of the LuSens test method, in a formal inter-laboratory study according to the OECD 
guidance document No. 34 (OECD, 2005). The point of reference is the KeratinoSens™ assay.  
The primary aim was on its transferability and reproducibility (within and between laboratories) in a 
multi-laboratory ring trial (goal 1).  
The secondary aim was to preliminary evaluate the accuracy of the method in discriminating 
sensitisers and non-sensitisers (according to UN GHS for classification and labelling of chemicals for 
skin sensitisation (cat. 1; no cat.) (UN, 2015) and ECR No. 1272/2008 on classification, labelling and 
packing of substances and mixtures (EC, 2008)) (goal 2). 
 
(b) Appraisal of the clarity of study objective as outlined in the Test Submission 
The study objective, as well as both aims, is sufficiently clear to allow persons skilled in the process of 
validation of cell-based test methods to understand. 
 
1.2 Quality of the background provided concerning the purpose of the test method  
The LuSens test method is considered to be a potentially important component of the safety 
evaluation of chemicals. Skin sensitisation assessment represents a standard requirement of 
chemical legislation (UN GHS for classification and labelling of chemicals for skin sensitisation (cat. 1; 
no cat.) (UN, 2015) and ECR No. 1272/2008 on classification, labelling and packing of substances and 
mixtures (EC, 2008)). 
The drive behind the development of test method similar to the KeratinoSens™ assay was the need 
(according to the developers) of a test method free of licensing or any measure of protection. This 
will be published at the BASF home page. 
 
(a) Analysis of the scientific rationale provided in the Test Submission 
The scientific background of the LuSens is identical to the background of the KeratinoSens™ assay, 
which recently became an OECD test guideline (OECD, 2015a). Both methods exploit the central role 
of Nrf-2 transcription factor activity in the development of skin sensitisation.  
It is well known that cysteine-reactive skin sensitisers activated the Nrf-2/KEAP1 pathway, resulting 
in the increase in Nrf-2 activity. This activation can be mimicked in vitro by employing a reporter gene 
for luciferase (instead of the Nrf-2 transcription factor) under the control of an antioxidant response 
element (ARE). The measured endpoint is the upregulation of luciferase activity after 48 hrs of 
exposure. This sequence of events was outlined by the test submitters in a concise but precise way. 
The provided scientific background profiles the LuSens as a test method covering key event 2 of the 
OECD Adverse Outcome Pathway for Skin Sensitisation (OECD, 2012). 
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(b) Analysis of the regulatory rationale provided in the Test Submission 
The provided regulatory rationale builds largely on the Cosmetics Regulation, and the emergence and 
application of OECD test guidelines in the context of REACH. 
Skin sensitisation assessment represents a standard requirement of chemical legislation (UN GHS for 
classification and labelling of chemicals for skin sensitisation (cat. 1; no cat.) (UN, 2015) and ECR No. 
1272/2008 on classification, labelling and packing of substances and mixtures (EC, 2008)). 
 
1.3 Appraisal of the appropriateness of the study design 
Pre-validation of the LuSens test method, in a formal inter-laboratory study according to the OECD 
guidance document No. 34 (OECD, 2005) and is based on Performance Standards (OECD, 2015b). The 
point of reference is the KeratinoSens™ assay. 
Four laboratories were involved in the study, instead of the required minimum of three.   
In Phase I (transferability) 8 non-coded substances were tested. This phase contained the relevant 
steps: SOP assessment, regular meetings, training.  
Moving forward to the next phase the participating laboratories had to comply with two criteria: 
1. An ‘acceptable’ number of valid repetitions, set to be > 70 %; 
2. 6/8 substances correctly predicted.  
In Phase II (reproducibility) 20 coded reference substances were tested. All the measures required 
for proper assessment of test method reproducibility were taken: independent test substance 
distributor (BioTesys) and independent biostatistician (S. Hoffmann), substances of Phase II were 
provided with an independently generated code by the biostatistician, no communication between 
the laboratories. 
A safety officer was appointed in each laboratory and provided with an envelope containing the data 
sheets for the blinded substances.  
All participating laboratories were GLP compliant. The testing was performed under GLP-like 
conditions, but without a specific quality assurance officer for each of the laboratories for confirming 
the quality of the data. This task was performed by the biostatistician who was not GLP accredited.  
 
1.4 Appropriateness of the statistical evaluation 
The data were collected to the lead laboratory, transferred into a predefined data analysis template 
and analysed by S. Hoffmann. 
The compliance by the laboratories with the assay and result acceptance criteria was assessed by the 
biostatistician before analysis of reproducibility and transferability. 
The statistical approaches applied were appropriate for the purpose of this Performance Standards-
based type of study.  
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2. Collection of existing data 
2.1 Existing data used as reference data 
Performance standards of the OECD TG 442D (OECD, 2015a) were employed according to the OECD 
Series on Testing and Assessment No. 213 – Performance Standards for assessment of proposed 
similar or modified in vitro skin sensitisation ARE-Nrf2 luciferase test methods (OECD, 2015b). 
 
2.2 Existing data used as testing data 
See Section 2.1. 
 
2.3 Search strategy for retrieving existing data 
See Section 2.1. 
 
2.4 Selection criteria applied to existing data 
See Section 2.1. 
 
 
3. Quality aspects relating to data generated during the study 
3.1 Quality assurance systems used when generating the data 
See section 1.3. 
 
3.2 Quality check of the generated data prior to analysis 
The compliance by the laboratories with the assay and result acceptance criteria was assessed by the 
biostatistician before analysis of transferability and reproducibility.  
 
 
4. Quality of data used for the purpose of the study (existing and 
newly generated) 
4.1 Overall quality of the evaluated testing data (newly generated or existing) 
Overall, application of the quality and acceptance criteria to the test system seems to assure good 
quality data.  
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4.2 Quality of the reference data for evaluating relevance1 
Performance standards of the OECD TG 442D (OECD, 2015a) were employed according to the OECD 
Series on Testing and Assessment No. 213 – Performance Standards for assessment of proposed 
similar or modified in vitro skin sensitisation ARE-Nrf2 luciferase test methods (OECD, 2015b). 
4.3 Sufficiency of the evaluated data in view of the study objective 
Performance standards of the OECD TG 442D (OECD, 2015a) were employed according to the OECD 
Series on Testing and Assessment No. 213 – Performance Standards for assessment of proposed 
similar or modified in vitro skin sensitisation ARE-Nrf2 luciferase test methods (OECD, 2015b). 
The overall quality of the data is sufficient to draw conclusions on the transferability and 
reproducibility (within as well as between laboratories).  
5. Test definition (Module 1)
The test method is adequately described, and covers the parameters that are relevant for good test 
performance. 
1. The test description specifies the cell line used for the test.
2. The relevance of the endpoints (cell viability and luciferase activity) measured is explained
against the background of the available scientific knowledge.
3. Quality and acceptance criteria for untreated cells, as well as positive and negative controls,
are described.
4. Acceptance criteria for the results are outlined extensively.
5. The prediction model is clearly formulated.
6. The occurrence of non-qualified tests was calculated to be between 0 % and 22 %. Failure
seems often to be related to high cytotoxicity.
6. Test materials
6.1 Sufficiency of the number of evaluated test items in view of the study objective 
See Section 2.1. 
6.2 Representativeness of the test items with respect to applicability 
See Section 2.1. 
1
 OECD guidance document No. 34 on validation defines relevance as follows: "Description of relationship of the 
test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to 
which the test correctly measures or predicts the biological effect of interest. Relevance incorporates 
consideration of accuracy (concordance) of a test method." 
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7. Within-laboratory reproducibility (WLR) (Module 2) 
7.1 Assessment of repeatability and reproducibility in the same laboratory  
 12 test substances from the Performance Standards for the ARE-Nrf2 luciferase test methods 
were evaluated coded (OECD, 2015b). 
 WLR was based on the concordance of classification of three independent experiments, each 
consisting of at least two independent repetitions, performed by 3 laboratories.  
 The WLR was very good as far as the overall binary classification (Y/N) is concerned (100 %). 
 
7.2 Conclusion on within-laboratory reproducibility as assessed by the study 
Overall, the WLR is very good. 
 
 
8. Transferability (Module 3) 
8.1 Quality of design and analysis of the transfer phase 
Eight test substances were selected for the transfer phase (Phase I). Four laboratories were involved, 
of which two had been part of the KeratinoSens™ validation study. One experiment was performed. 
The training programme protocol provided was adequate.  
For moving forward to Phase II the participating laboratories had to comply with two criteria: 
1. An ‘acceptable’ number of valid repetitions, set to be > 70 %; 
2. 6/8 substances correctly predicted. 
 
8.2 Conclusion on transferability to a naïve laboratory / naïve laboratories as assessed by 
the study 
Based on the transferability report and the data of the BLR assessment, the transfer of the test 
method to the participating laboratories can be considered successful. 
 
 
9. Between-laboratory reproducibility (BLR) (Module 4) 
9.1 Assessment of reproducibility in different laboratories 
The BLR was assessed based on twenty reference chemicals recommended in the OECD Performance 
Standards for assessment of proposed similar or modified in vitro skin sensitisation ARE-Nrf2 
luciferase test methods (OECD, 2015b). 
 12 test substances were evaluated by 3 laboratories (lead, L1 and L2) in the context of the WLR 
assessment, in three independent experiments, and eight were tested in 3 laboratories (lead, L3 
and L4) in the context of the BLR assessment, in one experiment. L3 and L4 tested also five of 
the twelve WLR test substances. 
 The data revealed a BLR of 100 %. 
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9.2 Conclusion on between-laboratory reproducibility as assessed by the study 
The BLR is very good as far as the overall binary classification (Y/N) is concerned is concerned.  
 
 
10. Predictive capacity and overall relevance (Module 5)  
10.1 Adequacy of the assessment of the predictive capacity in view of the purpose 
The predictive capacity of LuSens was assessed on the basis of the inter-laboratory validation study 
(N = 20 reference substances). 
Performance Standards based study 
The laboratories tested different number of substances (lead: 20, L1: 12, L2:12, L3: 13, L4: 13) 
Predictive capacity against all data (KeratinoSens™ data in brackets) 
o Sensitivity: 92 %, 88 %, 88 %, 100 %, 100 % (83.3 %) 
o Specificity: 75 %, 75 %, 75 %, 86 %, 86 % (87.5 %) 
o Accuracy: 85 %, 83 %, 83 %, 92 %, 92 % (85 %) 
The differences in predictive performance between the laboratories, in spite of 100 % WLR and BLR, 
is due to the fact that the laboratories tested different subsets of the 20 reference substances. The 
increase in sensitivity and specificity was explained by lack of testing of the false negative (phenyl 
benzoate) and false positive (4-methoxy-acetophenone by laboratories) by L3 and L4. 
Additional information on 74 chemicals from an internal BASF study showed a sensitivity of 74 %, 
specificity of 74 % and accuracy of 74 % compared to the LLNA. 
A comparative study performed by EURL ECVAM using 49 chemicals revealed a sensitivity of 64 %, 
specificity of 69 % and accuracy of 65 % for LuSens, and a similar sensitivity of 73 %, specificity of     
69 % and accuracy of 71 % for KeratinoSens™. 
 
10.2 Overall relevance (biological relevance and accuracy) of the test method in view of 
the purpose 
In terms of specificity the LuSens does not fulfil the Performance Standards requirements (≥ 80 %).  
However, eugenol is an 'incorrect' prediction as compared to KeratinoSens™, but a correct prediction 
as compared to the LLNA. This results in a higher sensitivity of LuSens compared to KeratinoSens™, 
and well above the required 80 %. 
Overall, the accuracy of both test methods at 85 % is the same for the 20 reference substances. On 
larger sets of substances the performance values drop markedly for both test methods. 
Research has shown that borderline substances like methyl salicylate and eugenol may be classified 
as both sensitisers and non-sensitisers in repeated tests using the same assay (Kolle et al., 2013). 
Indeed, careful analysis of the individual run data for methyl salicylate and eugenol showed that both 
sensitiser and non-sensitiser predictions occurred with either KeratinoSens™ or LuSens (Table 1). 
 
ESAC WORKING GROUP REPORT  Page | 35 
Table 1: Overview of the individual runs obtained with LuSens and Keratinosens™ for the 20 
reference substances. 
 
P = Positive run 
N = Negative run 
( ) = Tested in addition to what is requested in the PS 
( ) brackets correspond to an experiment, e.g., for experiment (N-P-P) the final conclusion is P. 
In bold face are the 12 reference substances for which, according to the PS, WLR information needs 
to be generated. BLR information in turn, is required for all 20 reference substances. 
 
Statistical analysis of the agreement between LuSens and KeratinoSens™ based on seven concordant 
final calls for non-sensitisers, eleven concordant final calls for sensitisers, and two discordant 
substances reveals a Fleiss’ Kappa value of 0.794 (95 %-CI from 0.528 to 1). This Kappa value suggests 
that both assays show substantial (0.61 ≤ ĸ ≤ 0.80) if not almost perfect (0.81 ≤ ĸ ≤ 1.00) agreement. 
As already published (Urbisch et al., 2015), LuSens and KeratinoSens™ can be regarded as 
interchangeable in an integrated/defined approach to testing and assessment. On the basis of 18 out 
of 20 reference substances being classified correctly, and the two discordant substances being 
borderline substances (Kolle et al., 2013), the ESAC WG cannot see any scientific reason for choice of 
one method over the other, suggesting informed test method selection may be based more on price 
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and availability. The LuSens test developers agreed with the ESAC WG to specify on their web site 
that the cell line, as well as its quality assessment, are available free of charge. 
The ESAC WG concludes that the LuSens test method, like the KeratinoSens™ test method, is ready 
to be considered for regulatory use in the context of an Integrated Approach to Testing and 
Assessment (IATA) for skin sensitisation and remains a useful tool for screening and early decision 
making during product development, within the applicability domain defined in the validation study. 
 
 
11. Applicability domain (Module 6)  
11.1 Appropriateness of study design to conclude on applicability domain, limitations and 
exclusions 
The primary goal of the study was to assess transferability and reproducibility (WLR and BLR) of the 
test method.  
Nevertheless, some potential information on the applicability domain of the test method emerged 
from the studies discussed in Section 10. Furthermore, LuSens is bound to have the similar strengths 
and limitations as KeratinoSens™. 
 
11.2 Quality of the description of applicability domain, limitations, exclusions 
The proposed applicability domain includes Michael acceptors, Schiff base formers and nucleophilic 
substitutions.  
The ESAC WG disagrees with the inclusion of Schiff base formers into the applicability domain of the 
method on the basis that this requires an amine-group and not a thiol group.  After consultation with 
the test submitter, it was agreed to define the proposed applicability domain in terms of chemical 
classes applicable to skin sensitisation, rather than specific mechanistic domains. 
Specific limitations: 
1. Highly cytotoxic compounds may give rise to non-qualified tests. 
2. Low solubility/stability in aqueous solutions. 
3. Chemicals interfering with the MTT. 
4. Low accuracy with acylating agents. 
 
 
12. Performance standards (Module 7) 
12.1 Adequacy of the proposed Essential Test Method Components 
Not applicable. 
 
12.2 Adequacy of proposed Reference Chemicals 
Not applicable. 
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12.3 Adequacy of proposed performance target values 
The Performance Standards target values were set to be ≥ 80 % for sensitivity, specificity and 
accuracy, based on existing KeratinoSens™ performance data. 
The WLR (~86 % in one laboratory) and BLR (85 % - 91 % in five laboratories) of the KeratinoSens™ 
was considered very good (ESAC opinion on a Givaudan-coordinated study on the transferability and 
reliability of the KeratinoSens™ assay for skin sensitisation testing (2012)). However, it was also 
highlighted that this test method performs poorly on weak sensitisers: 41 % of the weak and 86 % of 
the very weak sensitisers were missed. Other research has shown that borderline substances like 
methyl salicylate and eugenol may be misclassified by the same test method (Kolle et al., 2013).  
To eliminate uncertainties concerning the prediction of borderline substances, the ESAC WG 
recommends that in PS-based assessments, the equivalence of a new method with the reference 
method(s) is evaluated side by side on the basis of the predictions for the individual reference 
chemicals instead of comparing sensitivity, specificity and accuracy to pre-specified threshold values. 
 
 
13. Readiness for standardised use 
13.1 Assessment of the readiness for regulatory purposes 
The provided data (good WLR, BLR and predictive capacity) suggest that the LuSens test method may 
be a useful component of a strategy for the regulatory testing and assessment of the skin sensitising 
potential of chemicals belonging to the applicability domain defined in the validation study. 
 
13.2 Assessment of the readiness for other uses  
The provided data (good WLR, BLR and predictive capacity) suggest that the LuSens test method can 
be used for screening and early decision making during product development. 
 
13.3 Critical aspects impacting on standardised use 
Proper training is required. 
 
13.4 Gap analysis 
None identified. 
 
 
14. Other considerations 
None. 
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15. Conclusions on the study 
15.1 ESAC WG summary of the results and conclusions of the study 
The study was performed according to the existing guidelines for a formal inter-laboratory study 
using Performance Standards (OECD, 2005; OECD, 2015b). The LuSens test method was easily 
transferred and showed a very good WLR (100 % concordance) and BLR (100 % concordance).  
In terms of specificity, LuSens does not fulfil the Performance Standards requirement (≥ 80 %). 
 
15.2 Extent to which study conclusions are justified by the study results alone 
The ESAC WG agrees with the conclusion by the VMT. However, Eugenol is an 'incorrect' prediction 
as compared to the KeratinoSens™, but a correct prediction as compared to the LLNA. This results in 
a higher sensitivity of the LuSens compared to KeratinoSens™, well above the required 80 %. Overall, 
the accuracy of both test methods is the same (85 %) for the 20 reference substances. 
 
15.3 Extent to which conclusions are plausible in the context of existing information 
Research has shown that borderline substances like methyl salicylate and eugenol may be 
misclassified in repeated evaluations using the same test (Kolle et al., 2013). Therefore, on the basis 
of the data from the 20 reference substances, the ESAC WG concludes that LuSens is relevant for the 
detection of skin sensitisers, but the low specificity would require its incorporation into a testing 
strategy, rather than its use as a standalone method. 
As already published (Urbisch et al., 2015), LuSens and KeratinoSens™ can be regarded as 
interchangeable in an integrated/defined approach to testing and assessment. Consequently, the 
ESAC WG cannot see any scientific reason for choice of one method over the other, suggesting that 
price and availability are the governing factors. The LuSens test developers agreed with the ESAC WG 
to specify on their web site that the cell line, as well as its quality assessment, are available free of 
charge.    
The provided data supported by the additional information suggest that the LuSens test method may 
be useful as a component of an IATA for skin sensitisation or as a tool for screening and early 
decision making during product development, for the assessment of chemicals belonging to the 
applicability domain defined in the validation study. 
It is recommended that in PS-based assessments, the equivalence of a new method with the 
reference method(s) is evaluated side by side on the basis of the predictions for the individual 
reference chemicals instead of comparing sensitivity, specificity and accuracy to pre-specified 
threshold values. 
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16. Recommendations 
16.1 General recommendations 
It is recommended that in PS-based assessments, the equivalence of a new method with the 
reference method(s) is evaluated side by side on the basis of the predictions for the individual 
reference chemicals instead of comparing sensitivity, specificity and accuracy to pre-specified 
threshold values. This would facilitate a direct assessment of the impact on the individual 
performance values of differences between similar test methods when borderline substances are 
tested. 
 
16.2 Specific recommendations (e.g. concerning improvement of SOPs) 
None. 
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